Ovarian cancer starts in the ovaries and often causes vague symptoms like bloating, pelvic pressure, or feeling full quickly. Many people with ovarian cancer notice changes over weeks to months, and symptoms can progress if not treated. It is more common after menopause, but it can occur at any adult age. Survival depends on the stage and tumor type, but outcomes improve with earlier diagnosis and modern care. Treatment often includes surgery and chemotherapy, and some benefit from targeted drugs like PARP inhibitors.
Overview
Ovarian cancerSymptoms
Ovarian cancer often causes vague, gradual symptoms. Early symptoms of ovarian cancer can include bloating, pelvic or belly pain, feeling full quickly, urinary urgency or frequency, fatigue, and back pain. Some notice changes in periods, constipation, or unexplained weight loss.
Outlook and prognosis
Many living with ovarian cancer want to know what to expect. Outcomes vary by stage at diagnosis, tumor type, and response to treatment; earlier-stage disease generally has better long-term survival. Modern surgery, targeted therapies, and maintenance treatments continue to improve remission length and quality of life.
Causes and risk factors
Ovarian cancer arises from DNA changes in ovarian cells. Risk increases with age, inherited BRCA1/BRCA2 or related mutations, strong family history, endometriosis, and reproductive factors like never being pregnant. Additional risks include obesity, long-term estrogen-only therapy, and smoking.
Genetic influences
Genetics play a major role in ovarian cancer. Inherited variants like BRCA1/BRCA2 and those linked to Lynch syndrome can greatly raise risk, sometimes prompting earlier screening or risk-reducing surgery. Tumor genetic testing also guides targeted treatments and clinical trial options.
Diagnosis
Doctors suspect ovarian cancer based on symptoms, pelvic exam, ultrasound, and blood tests such as CA‑125. CT or MRI assesses spread. A tissue sample taken during surgery confirms the diagnosis of ovarian cancer and guides treatment.
Treatment and drugs
Ovarian cancer care is usually a combination approach. Most people have surgery to remove as much cancer as possible, then chemotherapy; some receive targeted therapies, maintenance treatment, or hormone therapy based on tumor testing. Clinical trials and supportive care can also be part of treatment.
Symptoms
Symptoms of ovarian cancer often feel vague and easy to dismiss, especially early on. You might notice small changes at first: persistent bloating, needing to urinate more often, or feeling full sooner than usual. What often stands out is that early symptoms of ovarian cancer are new for you, happen frequently, and stick around for weeks rather than days. Many of these symptoms overlap with common conditions, but their persistence and pattern are what matter.
Your belly feels puffy or tight most days, not just after a big meal. Waistbands may feel snug even if your overall weight hasn’t changed. In ovarian cancer, this often builds gradually.
A dull ache or pressure low in the abdomen lingers. It may ebb and return but rarely fully settles. Some find it worsens with activity or by day’s end.
You feel full after small portions and may lose interest in food. Nausea or indigestion can tag along. This can be an early sign of ovarian cancer.
You need to urinate more often or feel urgent even when little comes out. There’s often no burning or infection on tests. Pressure from nearby swelling can irritate the bladder.
How people usually first notice Ovarian cancer?
Many people first notice ovarian cancer through subtle, everyday changes rather than a single dramatic symptom. The first signs of ovarian cancer often include persistent bloating, a feeling of fullness after small meals, pelvic or lower abdominal discomfort, needing to urinate more often or more urgently, and new constipation or diarrhea that doesn’t settle; some also notice unexplained fatigue or back pain. When these symptoms are new, happen more than a few times a week, and persist for several weeks, that pattern—especially in people after menopause—is the cue to check in with a clinician.
Types of Ovarian cancer
Ovarian cancer isn’t one single disease. Different types start in different ovarian cells and can behave differently, which affects symptoms, pace of growth, and treatment choices. Some types show early symptoms like bloating or pelvic pressure, while others stay quiet until they’re larger. Clinicians often describe them in these categories:
High‑grade serous
This fast‑growing type often starts in the fallopian tube cells and spreads early. Symptoms may include persistent bloating, pelvic or abdominal pain, and feeling full quickly. It’s the most common type of ovarian cancer in adults.
Low‑grade serous
Slower‑growing with more subtle, longer‑term symptoms like ongoing bloating or pelvic discomfort. It tends to affect younger adults more than other epithelial types. Treatment plans may include surgery and hormone‑based options.
Endometrioid
Linked with endometriosis in some people and may occur alongside uterine cancer. Abnormal vaginal bleeding, pelvic pain, or a new ovarian mass can be clues. Many cases are found at an earlier stage than high‑grade serous.
Clear cell
Can be associated with endometriosis and may form a solid mass. People may notice pelvic pain, pressure, or a persistent ache in the lower back. It can be less responsive to standard chemotherapy than other epithelial types.
Mucinous
Tumors can grow large and produce mucin, sometimes causing noticeable abdominal swelling. Early symptoms include bloating, changes in bowel habits, or pelvic pressure. Some are primary ovarian cancers, while others have spread from the gut.
Borderline tumors
These epithelial tumors have abnormal cells but lack clear invasion into surrounding tissue. Symptoms can be mild and include a pelvic mass or bloating. They often have a better outlook than invasive ovarian cancer types.
Granulosa cell
A sex‑cord stromal tumor that can produce estrogen. Signs may include irregular bleeding, breast tenderness, or a pelvic mass. These tumors often grow slowly and can recur years later.
Sertoli‑Leydig cell
Rare stromal tumors that can make androgens (male‑type hormones). People may notice voice deepening, increased facial hair, or menstrual changes. Abdominal pain or a mass can also occur.
Dysgerminoma
A germ cell tumor that tends to affect teens and young adults. Symptoms include a rapidly enlarging pelvic mass, pain, or pressure. Blood tests may show elevated LDH, which helps with diagnosis and monitoring.
Yolk sac tumor
Fast‑growing germ cell tumor seen mostly in adolescents and young adults. Pelvic pain and a quickly enlarging mass are common, and alpha‑fetoprotein (AFP) is often high. These tumors usually respond well to chemotherapy.
Teratoma (immature)
Malignant germ cell tumor containing early‑type tissues. It can present with abdominal pain, a mass, or torsion from rapid growth. Treatment typically combines surgery with chemotherapy.
Mature teratoma
Also called dermoid cyst, this benign germ cell tumor is common in younger people. It may cause pelvic pain or torsion if it twists the ovary. Most are cured with surgery when needed, and they are not invasive types of ovarian cancer.
Small cell carcinoma
A very rare, aggressive ovarian cancer that may cause high calcium levels. Symptoms can include fatigue, constipation, confusion, or a pelvic mass. It often needs intensive, combined treatments.
Metastatic to ovary
Cancers from the stomach, colon, or breast can spread to the ovary. Symptoms resemble primary ovarian cancer—bloating, pain, or early fullness—but treatment focuses on the original cancer. Knowing these types of ovarian cancer helps guide testing and therapy.
What genetics can tell you about symptoms
Certain inherited variants in BRCA1 or BRCA2 can lead to earlier-onset ovarian cancer, often with vague symptoms like bloating, pelvic pressure, or feeling full quickly. Lynch syndrome gene changes (MLH1, MSH2, MSH6, PMS2) raise risk too, sometimes alongside abnormal bleeding.
Causes and risk factors
Risk factors for ovarian cancer include getting older and a strong family history. Inherited changes in BRCA1 or BRCA2, or Lynch syndrome, can raise your lifetime risk.
Endometriosis, higher body weight, and smoking may also increase ovarian cancer risk. Early first period, no pregnancies, late menopause, and estrogen-only therapy after menopause can also raise risk. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Many people want to know what raises the chance of ovarian cancer so they can understand their personal risk. Doctors often group risks into internal (biological) and external (environmental). Here, we focus on environmental risk factors for ovarian cancer and body-based factors that have been linked with higher risk. Knowing these can help you make sense of what your doctor may watch over time.
Risk rises as people get older, especially after menopause. Cells in the ovaries accumulate changes over time, making ovarian cancer more likely.
Having more years of ovulation (earlier first period and later menopause) is linked with higher risk. Each cycle triggers repair in ovarian tissue, and more cycles mean more chances for errors that can lead to cancer.
This condition can increase risk, particularly for certain cell types in the ovary. Ongoing inflammation and endometriomas (ovarian cysts related to endometriosis) may stress nearby cells over time.
Using estrogen-only hormone therapy after menopause has been linked with a higher risk. Longer duration of use appears to raise risk further.
Genetic risk factors
Inherited gene changes can play a major role in who develops ovarian cancer. The main genetic risk factors for ovarian cancer are inherited changes in certain DNA repair genes, especially BRCA1 and BRCA2. Carrying a genetic change doesn’t guarantee the condition will appear. Testing and family history patterns can help pinpoint who may benefit from genetic counseling.
BRCA1 variants: Changes in BRCA1 greatly raise lifetime risk of ovarian cancer. They are most linked to high-grade serous tumors and can lead to earlier onset. Relatives on either side of the family may be affected.
BRCA2 variants: Changes in BRCA2 also increase risk for ovarian tumors, though on average less than BRCA1. Families may also see breast and prostate cancers, which can be a clue. Men can carry and pass on these variants.
Lynch syndrome genes: Inherited faults in MLH1, MSH2, MSH6, PMS2, or EPCAM increase ovarian cancer risk, especially for certain subtypes. Risk size varies by gene and family history. Endometrial cancer in relatives can be another signal.
RAD51C and RAD51D: Variants in these DNA-repair genes give a moderate increase in ovarian cancer risk. They are often found in families with multiple ovarian cancers. Risk tends to rise with age.
BRIP1 gene: Harmful BRIP1 changes are tied to a moderate increase in ovarian risk. These variants are uncommon but important to look for during multi-gene testing.
PALB2 gene: PALB2 variants mainly raise breast cancer risk but may modestly increase ovarian risk. The size of risk is smaller than with BRCA1/2. Recommendations can differ by family history.
Peutz-Jeghers (STK11): Inherited STK11 changes cause Peutz-Jeghers syndrome and increase risk for certain ovarian tumors. These are often non-epithelial types, which behave differently from common ovarian cancers. Family patterns can be a clue.
Family history clues: Several relatives with ovarian or early breast cancer suggest an inherited risk. Patterns on either the mother’s or father’s side matter. These clues can help tailor which genes to test.
Ancestry and founders: Certain ancestries, such as Ashkenazi Jewish, Icelandic, or French Canadian, have higher chances of specific BRCA1/2 founder variants. This can raise inherited risk in those communities. Not everyone with this ancestry carries a variant.
Inheritance pattern: Most inherited risks follow an autosomal dominant pattern. A variant in just one copy of the gene can be enough to raise risk. Both men and women can carry and pass these variants.
Somatic (tumor) changes: Many ovarian cancers also develop genetic changes only in the tumor itself. These are not inherited and do not raise family risk. They can still influence treatment decisions.
Lifestyle risk factors
Several everyday behaviors can influence ovarian cancer risk, even though many cases are not directly caused by lifestyle alone. This overview focuses on lifestyle risk factors for ovarian cancer and highlights practical areas you can modify. Evidence varies by subtype, so risk changes may be modest but meaningful over time.
Higher body fat is linked to an increased risk of ovarian cancer, particularly certain subtypes. Gradual, sustained weight loss can lower inflammation and estrogen levels that may contribute to risk.
Prolonged sitting and low physical activity are associated with a higher risk. Regular moderate activity may help by improving insulin sensitivity and reducing chronic inflammation.
Cigarette smoking increases the risk of mucinous ovarian cancer. Quitting smoking can reduce harmful carcinogen exposure and improve overall gynecologic health.
Diets high in energy-dense, ultra-processed foods and low in fiber, fruits, and vegetables are linked with higher risk in some studies. Emphasizing fiber-rich plant foods may help lower systemic inflammation and estrogen reabsorption.
Risk prevention
You can lower your chance of ovarian cancer with a mix of medical choices and everyday habits. Prevention is about lowering risk, not eliminating it completely. What helps most depends on your personal and family history, including known inherited risks like BRCA or Lynch syndrome. For those at higher risk, specialist advice can point to stronger steps that meaningfully reduce risk.
Ask relatives about breast, ovarian, pancreatic, and prostate cancers on both sides of the family. Share this with your clinician so your ovarian cancer risk can be assessed.
If cancer runs in your family or you have high-risk ancestry, consider counseling and testing for genes like BRCA1/2 or Lynch. Results can shape your ovarian cancer prevention plan.
For very high-risk individuals, removing the fallopian tubes and ovaries after finishing family planning can cut ovarian cancer risk dramatically. It brings menopause, so timing and side effects should be discussed carefully.
Removing just the fallopian tubes during another planned pelvic surgery may lower future ovarian cancer risk. This keeps the ovaries in place and avoids sudden menopause.
Transmission
Ovarian cancer is not contagious—you can’t catch it or give it to someone else through touch, sex, kissing, or sharing a home. What can run in families is a higher chance of developing ovarian cancer, most often due to an inherited change in genes such as BRCA1 or BRCA2; roughly 1 in 5 ovarian cancers are linked to a hereditary gene change.
These changes can be passed down from your mother or your father and can be inherited by people of any sex, but they raise risk rather than guaranteeing cancer. A new gene change can also appear for the first time in a family. If you’re concerned about genetic transmission of ovarian cancer or how ovarian cancer is inherited, a genetics professional can discuss testing and personalized ways to lower risk.
When to test your genes
Consider genetic testing if ovarian cancer runs in your family, especially with multiple relatives or early diagnoses, or if you’re of Ashkenazi Jewish ancestry. Testing is also recommended for anyone diagnosed with ovarian, fallopian tube, or primary peritoneal cancer to guide treatment and inform relatives. A genetics professional can help choose the right test and timing.
Diagnosis
Most people reach testing after new abdominal symptoms or changes build up over weeks to months. You might notice small changes in daily routines, like feeling full sooner than usual, more frequent urination, or persistent bloating that doesn’t match your eating. Many wonder how ovarian cancer is diagnosed; it usually involves a mix of exams, imaging, and, when needed, a biopsy to confirm. The goal is to understand where it started and whether it has spread.
Doctors ask about bloating, pelvic pressure, early fullness, and changes in bathroom habits. Timing and triggers help decide which tests come first.
The clinician feels the ovaries and abdomen for lumps, tenderness, or fluid. Exam findings help prioritize imaging or urgent referral.
A small probe uses sound waves to look closely at the ovaries and pelvis. It shows cysts, solid areas, and blood flow, but cannot confirm cancer on its own.
CA-125 and other markers may be checked. Results support the overall picture but can be raised by noncancer causes like fibroids, endometriosis, or infection.
Stages of Ovarian cancer
Staging shows how far ovarian cancer has spread and helps tailor treatment and estimate outlook. Doctors usually determine the stage using imaging, blood tests, and findings from surgery and tissue samples. The process can involve several steps, each one adding to the picture. Final staging is often confirmed after an operation, when doctors can see the abdomen and test small tissue samples.
Stage I
Localized: Cancer is limited to one or both ovaries or the fallopian tubes. Early symptoms of ovarian cancer are often vague or absent, so it may be found during evaluation for other concerns. Outcomes are generally more favorable at this stage.
Stage II
Pelvic spread: Cancer has grown from the ovary or tube to nearby pelvic organs such as the uterus, bladder, or rectum. People may notice pelvic pain, pressure, or changes in urination or bowel habits. Treatment often combines surgery and chemotherapy.
Stage III
Abdominal spread: Cancer has reached the lining of the abdomen outside the pelvis and/or nearby lymph nodes. This stage can cause abdominal swelling, feeling full quickly, or fluid buildup in the belly. It usually requires surgery plus multi‑drug chemotherapy.
Stage IV
Distant spread: Cancer has spread to organs outside the abdomen or into the liver or spleen tissue, or to the lungs or fluid around the lungs. Symptoms can include shortness of breath or widespread effects beyond the abdomen. Care focuses on control, symptom relief, and targeted treatments when appropriate.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with ovarian cancer, outcomes depend on the stage at diagnosis, the tumor type, and how well surgery and chemotherapy remove or control visible disease. Early symptoms of ovarian cancer can be subtle—bloating, pelvic pressure, feeling full quickly—so many are diagnosed at a later stage, which lowers the chance of long-term remission. When caught early (confined to the ovaries), 5-year survival rates are high; when found after it has spread within the abdomen, survival decreases, though newer treatments are improving results.
Prognosis refers to how a condition tends to change or stabilize over time. Targeted therapies and maintenance treatments, such as PARP inhibitors for tumors with BRCA changes, have extended the time before the cancer returns for many people. Recurrence remains common, but some experience long stretches with little or no disease activity, especially when the tumor is sensitive to platinum-based chemotherapy. Even when cure isn’t possible, modern care can turn ovarian cancer into a condition managed over years, with planned treatment breaks and close monitoring.
Everyone’s journey looks a little different. Overall mortality is higher than for many other gynecologic cancers, particularly when diagnosed late, but survival has improved as care has advanced. Age, overall health, and genetic factors shape the outlook, and second opinions at high-volume centers can open doors to clinical trials and expert surgery. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Ovarian cancer can leave long-term effects that touch energy, digestion, sexual health, and emotions, even after treatment ends. Because the early symptoms of ovarian cancer are often vague, many learn about the disease later, which can shape what lingers over time. Long-term effects vary widely, and some fade while others persist or change. Many continue regular follow-up visits to watch for recurrence and manage late effects.
Many people feel deep tiredness that doesn’t fully lift with rest. Energy may improve over months, but some find stamina never returns to pre-cancer levels.
Tingling, numbness, or burning in the hands and feet can follow chemotherapy. These sensations may ease slowly or become long-lasting for some.
Trouble with memory, focus, or word-finding can appear after treatment. These thinking changes often improve, but mild “chemo brain” may persist.
Surgery or chemotherapy can trigger sudden menopause with hot flashes, sleep changes, and mood shifts. Bone thinning and vaginal dryness may follow over time.
How is it to live with Ovarian cancer?
Living with ovarian cancer often means moving through cycles of treatment and recovery while trying to protect time for ordinary life—work, rest, family moments, and small pleasures that steady the day. Fatigue, bloating, abdominal discomfort, and changes in appetite can shape what you feel able to do, and follow-up scans or blood tests can add a background hum of worry even during calmer stretches. Many find that leaning on a care team, supportive friends and family, and practical tools—like planning rest around treatment days, managing nausea proactively, and keeping an organized calendar—helps restore a sense of control. For loved ones, the best support is often being present, sharing tasks without overstepping, and listening closely to match help with what you actually need.
Treatment and drugs
Treatment for ovarian cancer usually combines surgery and chemotherapy, with the order depending on the cancer’s stage, your overall health, and whether surgeons can safely remove most of the tumor. Surgery often aims to remove the ovaries, fallopian tubes, uterus, nearby lymph nodes, and any visible cancer, followed by chemotherapy medicines that circulate through the body to kill remaining cancer cells. If the tumor has certain gene changes, targeted drugs or maintenance therapy may be added to help keep the cancer under control; when treatment is tailored to your genes, it’s often called personalized medicine. Alongside medical treatment, lifestyle choices play a role, including nutrition support, activity as you’re able, and help managing symptoms like nausea, pain, or fatigue. Not every treatment works the same way for every person, so your doctor can help weigh the pros and cons of each option and adjust your plan over time.
Non-drug treatment
Day-to-day care for ovarian cancer isn’t only about medicines—it’s also about practical steps that ease symptoms, protect function, and support your well-being. Alongside medicines, non-drug therapies can make treatment more tolerable and life feel more manageable. The right mix depends on your stage, goals, and any side effects you’re facing. Your team can help tailor these options to your needs and preferences.
Removing as much tumor as safely possible can ease pressure, pain, or bloating. It also helps plan next steps by showing how far ovarian cancer has spread.
Targeted beams can shrink painful spots or control bleeding. It’s often used to relieve symptoms from ovarian cancer in a specific area.
A genetics expert reviews your personal and family history and may arrange testing. Results can guide ovarian cancer care and help relatives understand their own risks.
Before treatment, specialists can discuss egg or embryo freezing and other options. This helps align ovarian cancer care with your future family plans.
Your genes may have an impact on how drugs work for you
Your genes can affect how your body handles key ovarian cancer drugs—how fast you break them down, how strong the effect is, and whether side effects hit harder. Doctors may use genetic tests to guide dosing or choose alternatives that fit your biology.
Pharmacological treatments
Ovarian cancer is often treated with a mix of chemotherapy and targeted drugs tailored to the tumor type, stage, and any inherited or tumor‑specific gene changes. First-line medications are those doctors usually try first, based on strong evidence and safety. For many, first-line medications for ovarian cancer include a platinum drug paired with a taxane, and some also receive a targeted medicine or maintenance therapy afterward. Treatments can also change over time if the cancer returns or if side effects become hard to manage.
This is the most common first-line chemotherapy combination, usually given by IV every 3 weeks. It can cause hair loss, fatigue, numbness in fingers or toes, and temporary drops in blood counts.
This targeted drug blocks blood vessel growth to the tumor and can be added to chemotherapy and continued afterward as maintenance. Side effects can include high blood pressure, headache, and rare risks like bleeding or bowel perforation.
Olaparib, niraparib, and rucaparib can help keep the cancer controlled after it shrinks with chemotherapy, especially in those with BRCA mutations or homologous recombination deficiency. Common effects include fatigue, nausea, and low red blood cells; regular blood tests are needed.
This platinum drug may be used when carboplatin is not suitable or in certain treatment plans. It can cause more nausea, kidney strain, and nerve tingling, so hydration and careful monitoring are important.
Genetic influences
If close relatives have had ovarian or breast cancer, inherited gene changes may be part of the picture. About 15% to 20% of ovarian cancer is linked to gene variants passed down in families, most often in BRCA1 or BRCA2, and sometimes in DNA‑repair genes associated with Lynch syndrome. These changes can raise lifetime risk well above the average 1–2%, with BRCA1 often carrying the highest risk and BRCA2 and some others causing a more moderate increase. Having a gene change doesn’t always mean you will develop the condition. Genetic counseling and genetic testing for ovarian cancer risk can clarify your personal risk and whether relatives could be affected. Results can also guide the timing of risk‑reducing steps, such as considering preventive surgery after family planning, and help family members decide whether testing makes sense for them.
Is Ovarian cancer genetic?
Genetics play a major role in ovarian cancer. Inherited variants like BRCA1/BRCA2 and those linked to Lynch syndrome can greatly raise risk, sometimes prompting earlier screening or risk-reducing surgery. Tumor genetic testing also guides targeted treatments and clinical trial options.
Pharmacogenetics—how genetics influence drug effects
For ovarian cancer, treatment choices increasingly depend on the genes found in the tumor and, at times, in your inherited DNA. Changes in BRCA1 or BRCA2, and in other genes that help repair DNA, often mean the cancer is more sensitive to platinum chemotherapy and make a class of targeted drugs called PARP inhibitors a strong maintenance option after response. Many centers also use a broader homologous recombination deficiency (HRD) test to estimate how likely PARP inhibitors such as olaparib, niraparib, or rucaparib are to help.
A small subset of ovarian cancers have mismatch-repair deficiency or are MSI-high, which can open the door to immunotherapy medicines. Alongside your medical history and treatment goals, genetic testing for ovarian cancer treatment decisions can guide whether to pursue targeted drugs, clinical trials, or standard chemotherapy. Genes that affect how the body handles paclitaxel or other chemotherapy are being studied, but routine pharmacogenetic testing for dosing isn’t standard yet, so your team will fine-tune treatment based on side effects and blood tests during care.
Interactions with other conditions
Living with ovarian cancer alongside other health issues can shape how it’s found and treated day to day. Conditions like endometriosis or irritable bowel syndrome can blur the picture and delay noticing early symptoms of ovarian cancer, since pelvic pain, bloating, and bowel changes may already be part of the background. Blood clots are more common in ovarian cancer, so being on blood thinners or having heart or lung disease can change surgery and chemotherapy plans and raise bleeding or breathing risks. Shared genetic variants may explain why certain conditions cluster together, such as BRCA1/2 changes linking ovarian cancer with breast cancer and Lynch syndrome linking it with colorectal and uterine cancers. Metabolic conditions like obesity or diabetes can raise surgical risks and affect how the body handles chemotherapy, while kidney or liver problems may limit which drugs and doses are safest. If you live with endometriosis, polycystic ovary syndrome, or prior hormone therapy, discuss how those histories might influence screening, symptoms, or treatment choices for ovarian cancer.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described abdominal fullness, pelvic pain, or unexpected bleeding in women, long before anyone could see tumors hidden deep in the pelvis. Families sometimes remembered an aunt who “slowed down,” lost weight, and needed repeated fluid drained from her belly—signs we now recognize as possible late effects of ovarian cancer. Doctors could feel enlarged ovaries by exam in some cases, but for most of the past two centuries, the disease remained largely out of sight until it was advanced.
First described in the medical literature as growths on the “female glands,” ovarian cancer was initially grouped with other pelvic tumors because there were no reliable ways to tell them apart. In the late 1800s and early 1900s, improvements in surgery and anesthesia allowed surgeons to remove diseased ovaries, and pathologists began to classify different tumor types under the microscope. Over time, descriptions became more refined, separating ovarian cancer from conditions like cysts or benign masses, and noting that many cases were found only after symptoms became persistent.
By the mid-20th century, pap tests helped prevent many cervical cancers, but they did not detect ovarian cancer. This contrast sharpened awareness that ovarian cancer often presents late. As medical science evolved, researchers tracked patterns: risk increased with age, childbirth and breastfeeding seemed protective, and birth control pills lowered risk. Generations of similar symptoms in some families led clinicians to suspect an inherited form.
In recent decades, knowledge has built on a long tradition of observation. DNA research now explains why some families carry a much higher risk: changes in genes like BRCA1 and BRCA2 raise the chance of ovarian and breast cancers. At the same time, scientists realized that many “ovarian” cancers actually start in the far end of the fallopian tube, then spread to the ovary and nearby surfaces. This shifted thinking about where early changes occur and why early symptoms of ovarian cancer are so hard to spot.
With each decade, tools improved. Ultrasound, CA-125 blood tests, and better imaging helped doctors monitor suspicious findings, though no general screening test has proven effective for everyone. Surgical techniques moved toward careful staging and cytoreduction—removing as much tumor as possible—paired with chemotherapy. More recently, targeted medicines such as PARP inhibitors have offered new options, especially for people with specific genetic changes.
Looking back helps explain today’s approach: notice persistent bloating, pelvic pressure, or changes in appetite; know your family history; and consider genetic counseling if close relatives had ovarian, breast, pancreatic, or prostate cancers. The way ovarian cancer has been understood has changed, yet the goal remains steady—find it earlier when possible and tailor care to each person’s biology and life.